BioSpace News Archive

There is currently only one FDA-approved DC vaccine available on the market and it is dedicated to the treatment of prostate cancer.

Bruker Corporation (Nasdaq: BRKR) announced its TIMS DIA-NN software for the high-throughput, deep and unbiased 4D proteomics workflow. It now features the novel TIMScore algorithm which takes advantage of machine learning (ML) to predict CCS values of tryptic and phosphorylated peptides.

Quadrant Biosciences Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued the company and its partners, the SUNY Research Foundation and Penn State Research Foundation, U.S Patent No. 11,242,563 (Analysis of Autism Spectrum Disorder).

Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel anti-viral drugs against common respiratory viruses and global viral threats, today announced the inaugural members of its Scientific Advisory Board (SAB).

FDA Accepts Alvotech’s BLA Supporting Interchangeability for ATV02, a High Concentration, Citrate-Free Biosimilar Candidate for Humira ® .

Gossamer Bio, Inc. today announced that it will report its fourth quarter and full-year 2021 financial results on Thursday, March 3, 2022.

Stoke Therapeutics, Inc. announced that management will participate on the Orphan Neuro Panel at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET.

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced positive data from its expanded PLN-74809 Phase 1b proof-of-mechanism trial.

Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has confirmed its previously adopted positive opinion, recommending approval of PADCEV™.

Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics today announced a strategic collaboration to advance novel targeted protein degrader therapies to address important areas of medical need.